Results 11 to 20 of about 2,387 (195)

Administration of Nirsevimab for RSV Prophylaxis in Infants: A Comprehensive Review

Vaccines
Respiratory syncytial virus (RSV) is the primary etiological agent responsible for lower respiratory tract infections (LRTIs) and hospitalizations among infants. Nirsevimab, a novel monoclonal antibody (mAb), offers sustained protection against RSV for a
Fangrui Ding
exaly   +6 more sources

Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain [PDF]

Vaccines
Background/Objectives: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Nirsevimab has demonstrated to be a promising tool for preventing severe RSV disease.
Sara Jimeno, Adrián Peláez Laderas, Silvina Natalini Martinez   +2 more
exaly   +4 more sources

Parental Acceptance of Nirsevimab for RSV Prevention in Infants Across Two Consecutive Seasons in Emilia-Romagna, Italy [PDF]

Vaccines
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab, a long-acting monoclonal antibody, provides single-dose protection during the RSV season, but the ...
Susanna Esposito, Valentina Fainardi, Maria Elena Capra, Melodie O. Aricò, Angela Lanzoni, Francesco Accomando, Gaia Giorgia Arnesano, Cosimo Neglia, Enrico Valletta, Giacomo Biasucci, Serafina Perrone   +10 more
doaj   +3 more sources

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

Nature Communications, 2023
Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV ...
Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A. F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. Kelly, Tonya Villafana   +20 more
doaj   +2 more sources

Multicentre study on nirsevimab: Bayesian analysis reveals persisting risk for preterm infants [PDF]

BMJ Paediatrics Open
Objective To evaluate whether the timing and effectiveness of nirsevimab prophylaxis vary by gestational age.Design Retrospective cohort study conducted during two identical epidemic seasons: 2023–2024 (before nirsevimab introduction) and 2024–2025 ...
Federico Marchetti, Enrico Valletta, Gianluca Vergine, Silvia Bloise, Gina Ancora, Enrico Cocchi, Aurora Lorefice, Sara Zannoni, Benedetta Pellegrini, Francesco Saverio Morlupo, Beatrice Scarpellini, Melodie Olivia Loredana Rosa Aricò, Francesco Accomando, Marcello Stella   +13 more
doaj   +2 more sources

Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials

Pathogens
Background: Nirsevimab is approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season and in children aged ≤24 months who remain vulnerable to severe RSV
Amanda Leach, Robert J Kubiak, Tonya Villafana   +2 more
exaly   +3 more sources

Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study

Vaccines
Respiratory syncytial virus (RSV) infection is a frequent cause of hospitalisation in the first few months of life; however, this risk rapidly decreases with age.
Camino Trobajo-Sanmartín, Manuel García Cenoz, Juan C Muruzabal   +2 more
exaly   +3 more sources

A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults

Clinical and Translational Science
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) in infants worldwide. Nirsevimab, an extended half‐life monoclonal antibody against RSV, is approved in China for the prevention of RSV lower respiratory ...
Xiaomeng Mao, Xiaohan Hua, Chengyi Wu, Xiaoyun Ge, Jie Zhang, Xiaojie Wu, Robert J. Kubiak, Ulrika Wählby Hamrén, Tonya Villafana, Georgios Christou, Jannine Green, Therese Takas, Yuwen Jin   +12 more
doaj   +2 more sources

Real-world effectiveness of nirsevimab against respiratory syncytial virus in pediatric practice: the Piemonitorab study

Italian Journal of Pediatrics
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in pediatric populations, resulting in a substantial burden of disease.
Elisa Funiciello, Alessia Spadavecchia, Celeste Cagnazzo, Lorenza Ferrara, Bartolomeo Griglio, Antonino Sottile, Paola Berchialla, Franca Fagioli, on behalf of the Piemonitorab Study Group   +8 more
doaj   +2 more sources

Nirsevimab Treatment of RSV Bronchiolitis in Pediatric Emergency Departments

JAMA Network Open
New resistant mutations of respiratory syncytial virus type B (RSV-B) have been observed during the first year of implementation nirsevimab treatment. During the second season of implementation of nirsevimab treatment in France, RSV-B was predominant. To
De Mari, Pauline, Perceval, Lise Martin, Launay, Elise, Ouldali, Naim, Basmaci, Romain, Perceval, Lise, Martin, Aupiais, Camille, Rybak, Alexis, Cohen, Laure, de Pontual, Loic, Cohen, Robert, Lenglart, Lea, Levy, Corinne, Levieux, Karine, Béchet, Stéphane, Kramer, Rolf   +15 more
core   +4 more sources